Feb 25, 2013, 04.45 PM | Source: CNBC-TV18
SP Tulsian of sptulsian.com advised holding Ranbaxy Labs for two to three years. He feels the stock will see good appreciation.
SP Tulsian (more)
CEO, sptulsian.com | Capital Expertise: Equity - Fundamental ,IPO
Tulsian told CNBC-TV18, “Firstly if you simply ask me I would advice that if you have the willingness to hold Ranbaxy Labs I will simply say that yes hold it. Because if you really go by the financials of the company it is a USD 2.5 billion topline company with operating profit coming in close to about Rs 400 crore. I am not taking their foreign exchange gains and losses so maybe the struggle is happening on the Lipitor front.”
He further said, “First they recalled the medicine and now again they have resumed the production. When they recalled the Lipitor the share price corrected to Rs 410 in this last one month from Rs 460. But now even the technical factors are going in favour of the company that a lot of the short covering is seen. So, I will advice keeping a longer term horizon of maybe two to three years, this looks to be a very good case of appreciation.”
“But if you want to have a relative performance by moving into the other pharma stocks then one stock which comes in my mind where shift can be taken is Glenmark . You can move from Ranbaxy to Glenmark maybe at a level of about Rs 444-445 and you may see the better gain coming in, in case of Glenmark. However, on a standalone basis I don’t mind advising you to hold it Ranbaxy for two to three years,” Tulsian added.